Mannkind Corp (MNKD) 6.25 $MNKD
Abattis Bioceuticals Corp. Enters Into Share Agreement with Experion
ACCESSWIRE - Thu Apr 17, 9:00AM CDT
On Apr. 16, Abattis Bioceuticals Corp. (OTCPINK: ATTBF) share volume soared, with 1,166,632 changing hands, significantly higher than its three-month average
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...
Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund
ACCESSWIRE - Tue Apr 15, 9:01AM CDT
Elite Pharmaceuticals Inc. (OTCBB: ELTP) announced Apr. 14 that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund LLC ("LPC"
, a Chicago-based institutional investor for up to $40 million.
Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 6:52PM CDT
Most investors realize that share price is meaningless when comparing companies. A company at $50 per share might actually be worth more than a company at $100 per share because a company's value is determined by the number of outstanding shares in...
Look for Shares of MannKind to Potentially Rebound after Yesterday's 1.87% Sell Off
Comtex SmarTrend(R) - Mon Apr 14, 5:31PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $6.15 to a high of $6.58. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $6.31 on volume of 9.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MannKind's Overly-Optimisitic Investors
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:47PM CDT
Last week, MannKind announced that the Food and Drug Administration was delaying a decision about whether to approve its inhaled insulin Afezza by three months. Investors seemed surprised, with shares falling 8% on Monday, although it made all...
Critical Alerts For Walt Disney, Walgreen, BioMarin Pharmaceuticals, Canadian Solar, and MannKind Released By InvestorsObserver
PR Newswire - Mon Apr 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for DIS, WAG, BMRN, CSIQ, and MNKD.
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 1:10PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
MannKind (MNKD) Stock Continues Decline Today
at The Street - Fri Apr 11, 2:25PM CDT
MannKind (MNKD) continued its decline Friday after news that rival biopharmaceutical company Dance Biopharm had filed a $75 million IPO on Wednesday night as it seeks money to continue developing an inhaled insulin device. MannKind's own inhaled...
FDA Recommendations, Study Publications, Recognitions, Agreements, and Acquisitions - Analyst Notes on MannKind, Acceleron, Steris, Retrophin, and NxStage Medical
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding MannKind Corp. (NASDAQ: MNKD), Acceleron Pharma, Inc. (NASDAQ: XLRN), Steris Corp. (NYSE: STE), Retrophin, Inc. (NASDAQ: RTRX), and NxStage Medical, Inc. (NASDAQ: NXTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
One Factor Driving MannKind (MNKD) Stock Down Today
at The Street - Thu Apr 10, 1:40PM CDT
MannKind (MNKD) dipped Thursday amid news that rival biopharmaceutical company Dance Biopharm had filed a $75 million IPO on Wednesday night as it seeks money to continue developing an inhaled insulin device. MannKind's own inhaled insulin device,...
MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO
at The Street - Thu Apr 10, 10:52AM CDT
Dance Biopharma is developing a device which sends vaporized insulin liquid into a patient's lungs.
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick" announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst.
'Fast Money' Recap: A Rational Rally
at The Street - Thu Apr 10, 4:00AM CDT
The trading panel discussed which stocks caught a bounce and which may never make new highs.
Watch for MannKind to Potentially Pullback After Gaining 7.03% Yesterday
Comtex SmarTrend(R) - Wed Apr 09, 4:14PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $6.51 to a high of $7.10. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $7.01 on volume of 17.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
MNKD July 19th Options Begin Trading
at The Street - Tue Apr 08, 10:17AM CDT
Investors in MannKind Corp saw new options become available today, for the July 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 102 days until expiration the newly...
Company News for April 08, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 9:06AM CDT
Companies in the News are: QCOR,MNK,GAS,MNKD,PBR
Will This Coverage Initiation Help MannKind (MNKD) Stock Today?
at The Street - Tue Apr 08, 8:20AM CDT
MannKind (MNKD) had coverage initiated on its shares with a 'market perform' rating by Brinson Patrick
Abattis Bioceuticals Corp. Enters Into Share Agreement with Experion
ACCESSWIRE - Thu Apr 17, 9:00AM CDT
On Apr. 16, Abattis Bioceuticals Corp. (OTCPINK: ATTBF) share volume soared, with 1,166,632 changing hands, significantly higher than its three-month average
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 16, 9:07AM CDT
The selloff in the biotech sector continued with overall sentiment remaining bearish.
5 Unlikely Companies Bucking the Biotech Sell-Off
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 15, 11:05AM CDT
Over the past month biotech stocks have been absolutely bludgeoned, with the SPDR S&P Biotech ETF down 22.4%. I've offered my two cents on the subject previously and surmised the the dramatic fall is based on some combination of unrealistic...
Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund
ACCESSWIRE - Tue Apr 15, 9:01AM CDT
Elite Pharmaceuticals Inc. (OTCBB: ELTP) announced Apr. 14 that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund LLC ("LPC"
, a Chicago-based institutional investor for up to $40 million. Valuation Doesn't Equal Share Price (and That Goes Double for Biotech)
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 6:52PM CDT
Most investors realize that share price is meaningless when comparing companies. A company at $50 per share might actually be worth more than a company at $100 per share because a company's value is determined by the number of outstanding shares in...
Look for Shares of MannKind to Potentially Rebound after Yesterday's 1.87% Sell Off
Comtex SmarTrend(R) - Mon Apr 14, 5:31PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $6.15 to a high of $6.58. Yesterday, the shares fell 1.9%, which took the trading range below the 3-day low of $6.31 on volume of 9.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
MannKind's Overly-Optimisitic Investors
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:47PM CDT
Last week, MannKind announced that the Food and Drug Administration was delaying a decision about whether to approve its inhaled insulin Afezza by three months. Investors seemed surprised, with shares falling 8% on Monday, although it made all...
Critical Alerts For Walt Disney, Walgreen, BioMarin Pharmaceuticals, Canadian Solar, and MannKind Released By InvestorsObserver
PR Newswire - Mon Apr 14, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for DIS, WAG, BMRN, CSIQ, and MNKD.
This Week in Biotech: The Questcor Buyout and MannKind's Giant Leap to Nowhere
Sean Williams, The Motley Fool - Motley Fool - Sat Apr 12, 1:10PM CDT
With the SPDR S&P Biotech Index up 22% over the trailing-12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and...
MannKind (MNKD) Stock Continues Decline Today
at The Street - Fri Apr 11, 2:25PM CDT
MannKind (MNKD) continued its decline Friday after news that rival biopharmaceutical company Dance Biopharm had filed a $75 million IPO on Wednesday night as it seeks money to continue developing an inhaled insulin device. MannKind's own inhaled...
FDA Recommendations, Study Publications, Recognitions, Agreements, and Acquisitions - Analyst Notes on MannKind, Acceleron, Steris, Retrophin, and NxStage Medical
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding MannKind Corp. (NASDAQ: MNKD), Acceleron Pharma, Inc. (NASDAQ: XLRN), Steris Corp. (NYSE: STE), Retrophin, Inc. (NASDAQ: RTRX), and NxStage Medical, Inc. (NASDAQ: NXTM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
One Factor Driving MannKind (MNKD) Stock Down Today
at The Street - Thu Apr 10, 1:40PM CDT
MannKind (MNKD) dipped Thursday amid news that rival biopharmaceutical company Dance Biopharm had filed a $75 million IPO on Wednesday night as it seeks money to continue developing an inhaled insulin device. MannKind's own inhaled insulin device,...
MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO
at The Street - Thu Apr 10, 10:52AM CDT
Dance Biopharma is developing a device which sends vaporized insulin liquid into a patient's lungs.
Brinson Patrick Re-launches Research Department
PR Newswire - Thu Apr 10, 7:21AM CDT
Brinson Patrick Securities Corporation ("Brinson Patrick"
announced today that the firm has re-launched its equity research department with the recent initiation of coverage on several life sciences companies. The research effort is being spearheaded by Christopher James, M.D., Managing Director and Senior Equity Research Analyst. 'Fast Money' Recap: A Rational Rally
at The Street - Thu Apr 10, 4:00AM CDT
The trading panel discussed which stocks caught a bounce and which may never make new highs.
Watch for MannKind to Potentially Pullback After Gaining 7.03% Yesterday
Comtex SmarTrend(R) - Wed Apr 09, 4:14PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $6.51 to a high of $7.10. Yesterday, the shares gained 7.0%, which took the trading range above the 3-day high of $7.01 on volume of 17.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
MNKD July 19th Options Begin Trading
at The Street - Tue Apr 08, 10:17AM CDT
Investors in MannKind Corp saw new options become available today, for the July 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 102 days until expiration the newly...
Company News for April 08, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 9:06AM CDT
Companies in the News are: QCOR,MNK,GAS,MNKD,PBR
Will This Coverage Initiation Help MannKind (MNKD) Stock Today?
at The Street - Tue Apr 08, 8:20AM CDT
MannKind (MNKD) had coverage initiated on its shares with a 'market perform' rating by Brinson Patrick
